BeiGene Ltd. (49B) - Total Liabilities
Based on the latest financial reports, BeiGene Ltd. (49B) has total liabilities worth €2.34 Billion EUR (≈ $2.74 Billion USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BeiGene Ltd. - Total Liabilities Trend (2016–2024)
This chart illustrates how BeiGene Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See BeiGene Ltd. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
BeiGene Ltd. Competitors by Total Liabilities
The table below lists competitors of BeiGene Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coupang Inc.
F:788
|
Germany | €13.47 Billion |
|
LG Electronics Inc
KO:066570
|
Korea | ₩40.25 Trillion |
|
W. R. Berkley Corp
NYSE:WRB
|
USA | $33.91 Billion |
|
Cheniere Energy Partners LP
NYSE MKT:CQP
|
USA | $17.18 Billion |
|
AvalonBay Communities Inc
NYSE:AVB
|
USA | $10.41 Billion |
|
Dr Ing hcF Porsche AG
F:P911
|
Germany | €29.59 Billion |
|
Shriram Finance Limited
NSE:SHRIRAMFIN
|
India | Rs2.55 Trillion |
|
KONE Oyj
HE:KNEBV
|
Finland | €6.23 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down BeiGene Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BeiGene Ltd. (49B) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BeiGene Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BeiGene Ltd. (2016–2024)
The table below shows the annual total liabilities of BeiGene Ltd. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.59 Billion ≈ $3.03 Billion |
+14.14% |
| 2023-12-31 | €2.27 Billion ≈ $2.65 Billion |
+13.63% |
| 2022-12-31 | €2.00 Billion ≈ $2.33 Billion |
-16.94% |
| 2021-12-31 | €2.40 Billion ≈ $2.81 Billion |
+38.78% |
| 2020-12-31 | €1.73 Billion ≈ $2.02 Billion |
+173.14% |
| 2019-12-31 | €633.93 Million ≈ $741.14 Million |
+27.80% |
| 2018-12-31 | €496.04 Million ≈ $579.92 Million |
+36.93% |
| 2017-12-31 | €362.25 Million ≈ $423.51 Million |
+584.70% |
| 2016-12-31 | €52.91 Million ≈ $61.85 Million |
-- |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more